STOCK TITAN

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.

Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.

Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.

In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.

Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.

With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.

Rhea-AI Summary

Pfizer (PFE) and Valneva (VALN) have initiated a Phase 3 clinical study named VALOR to evaluate their investigational Lyme disease vaccine, VLA15, among 6,000 participants in Lyme-endemic areas in Europe and the U.S. This randomized, placebo-controlled trial aims to investigate the vaccine's efficacy, safety, and immunogenicity. VLA15 is the only Lyme vaccine candidate currently in clinical development, and prior studies have shown promising immunogenicity and tolerability. Pfizer plans to submit regulatory applications by 2025, upon successful trial completion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
-
Rhea-AI Summary

Pfizer announced the acquisition of Global Blood Therapeutics (GBT) for $68.50 per share in cash, totaling approximately $5.4 billion. This acquisition aims to enhance Pfizer's portfolio in sickle cell disease (SCD), addressing critical needs in this underserved community. GBT's Oxbryta, a first-in-class SCD treatment, generated $195 million in net sales in 2021. The combined franchise from both companies could exceed $3 billion in peak sales worldwide. The deal awaits stockholder and regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
-
Rhea-AI Summary

ViiV Healthcare announced week 240 results from the phase III BRIGHTE study of fostemsavir, demonstrating significant virologic responses in heavily treatment-experienced adults with multidrug-resistant HIV-1. The study involved 371 patients and found that 45% achieved virologic suppression. CD4+ cell counts increased by 296 cells/mm³, with 78% reaching counts of ≥200 cells/mm³. Safety profiles remained consistent, with 95% experiencing adverse events, primarily nausea and diarrhea. Fostemsavir serves as a crucial treatment option for patients facing limited alternatives due to resistance or safety issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
Rhea-AI Summary

ViiV Healthcare announced new findings from the HPTN 084 trial at the 24th International AIDS Conference, showing that cabotegravir long-acting (LA) for pre-exposure prophylaxis (PrEP) demonstrated an 89% lower rate of new HIV infections compared to daily oral tablets. No new HIV cases were reported among participants receiving cabotegravir during the unblinded period. Additionally, no birth defects were recorded among women who became pregnant post-injection. Cabotegravir LA is currently approved in the U.S. as Apretude.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
-
Rhea-AI Summary

ViiV Healthcare, majority owned by GSK and including Pfizer as a shareholder, has signed a new voluntary licensing agreement for cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP) to enhance access in low-income regions. This agreement allows selected generic manufacturers to produce cabotegravir LA for PrEP in 90 countries, following regulatory approval. With approximately 1.5 million new HIV cases annually, the long-acting injectable could significantly improve prevention efforts, particularly for women and adolescent girls.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
-
Rhea-AI Summary

Pfizer (NYSE: PFE) reported second-quarter 2022 revenues of $27.7 billion, a 47% increase, primarily driven by strong sales from Paxlovid and Comirnaty. Reported diluted EPS was $1.73, reflecting a 77% growth compared to Q2 2021. The company raised its full-year guidance for revenues to between $98.0 billion and $102.0 billion, despite foreign exchange headwinds. Pfizer emphasized its commitment to addressing global health needs while ensuring financial performance, with plans to acquire Biohaven and a focus on R&D investments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
Rhea-AI Summary

AM Best has reaffirmed the Financial Strength Rating of A (Excellent) and Long-Term Issuer Credit Rating of 'a+' (Excellent) for Blue Whale Re Ltd., with a stable outlook. The ratings reflect Blue Whale's strong balance sheet and operating performance, underscoring its crucial role as the captive insurer for Pfizer (PFE). Despite its reliance on Pfizer for capitalization and reinsurance, Blue Whale's operations are expected to maintain strong results. However, any shifts in Pfizer's support could impact Blue Whale's ratings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
none
-
Rhea-AI Summary

Pfizer Inc. (NYSE: PFE) has submitted a New Drug Application (NDA) to the FDA for PAXLOVID™, aimed at treating COVID-19 in high-risk patients. This follows data from the EPIC-HR study, which reported an 86% reduction in the risk of hospitalization or death. Notably, no deaths were recorded in PAXLOVID-treated patients through Week 24. The study highlights that 50-60% of the U.S. population carries risk factors for severe illness, reinforcing the drug's significance in combating COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
-
Rhea-AI Summary

Pfizer and BioNTech have secured a new vaccine supply agreement with the U.S. government for 105 million doses of COVID-19 vaccines. The deal is worth $3.2 billion, with doses to be delivered by Q4 2022, potentially including Omicron-adapted vaccines pending FDA authorization. The agreement allows for an additional 195 million doses if required. This effort aims to ensure access to vaccines as COVID-19 variants evolve and will continue to provide free vaccinations to eligible U.S. residents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
covid-19
Rhea-AI Summary

Roivant Sciences and Pfizer have launched Priovant Therapeutics to focus on developing innovative therapies for autoimmune diseases. Priovant is advancing brepocitinib, a dual inhibitor of TYK2 and JAK1, showing statistically significant results in five Phase 2 studies. A Phase 3 trial for dermatomyositis (VALOR) has commenced, and top-line results from an ongoing Phase 2b study in systemic lupus erythematosus (SLE) are expected in the second half of 2023. Pfizer retains a 25% equity stake in Priovant and has licensed rights for both brepocitinib and ropsacitinib.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none

FAQ

What is the current stock price of Pfizer (PFE)?

The current stock price of Pfizer (PFE) is $26.72 as of January 10, 2025.

What is the market cap of Pfizer (PFE)?

The market cap of Pfizer (PFE) is approximately 151.4B.

What is Pfizer Inc. known for?

Pfizer Inc. is known for its development, manufacturing, and distribution of prescription drugs and vaccines, including Prevnar 13, Ibrance, and Eliquis.

Where is Pfizer's headquarters located?

Pfizer's headquarters are located at The Spiral in Manhattan, New York City.

How much does Pfizer make annually?

Pfizer's annual sales are close to $50 billion, excluding COVID-19 product sales.

What are some of Pfizer's top-selling products?

Some of Pfizer's top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis.

What is the significance of Pfizer's international sales?

Pfizer's international sales represent nearly 50% of its total sales, with emerging markets being a major contributor.

What recent collaborations has Pfizer been involved in?

Pfizer has recently been involved in collaborations with Astellas and Merck to develop and commercialize cancer treatments like PADCEV™ and KEYTRUDA®.

When was Pfizer founded?

Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart.

What is Pfizer's approach to innovation?

Pfizer continually invests in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs.

How does Pfizer contribute to cancer treatment?

Pfizer contributes to cancer treatment through its development of innovative therapies and strategic collaborations, notably involving PADCEV™ and KEYTRUDA®.

What role do strategic partnerships play for Pfizer?

Strategic partnerships enhance Pfizer's market position, ensuring a steady pipeline of new and effective therapeutic solutions.
Pfizer Inc.

NYSE:PFE

PFE Rankings

PFE Stock Data

151.42B
5.66B
0.05%
67.79%
1.51%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW YORK